No Form 144 planned sale filings in the last 90 days
Beneficial Ownership (13D/13G)
No Schedule 13D/13G filings for this ticker
Material Events (8-K)
1
Filings (14d)
Data as of 2026-07-06
2026-07-06
AbbVie announced that its second-quarter 2026 earnings will include a $291 million pre-tax expense for acquired in-process research and development (IPR&D) and milestones, reducing both GAAP and adjusted earnings per share by $0.17. The company updated its adjusted earnings guidance for the quarter and the full year to reflect this charge. Its adjusted EPS is now expected to be between $3.57 and $3.61 for Q2, and between $13.91 and $14.11 for the full year.
Who are the top institutional investors holding ABBVIE INC (ABBV)?
Major stakeholders currently include BlackRock, Inc. ($32.8B), Vanguard Capital Management LLC ($25.0B), State Street CORP ($17.7B). Based on the latest 13F filings, there are a total of 4086 tracked investment funds and institutions maintaining positions in ABBV.
What is the overall institutional sentiment toward ABBV recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $20.3B, driven by 1860 managers accumulating shares while 1910 reduced their exposure.
Which institutions have been selling or reducing their ABBV positions?
In the latest period, 1713 funds trimmed their holdings, and 197 managers completely exited their positions. The aggregate reported sell value was $145.3B.
Are there any notable investors adding ABBV to their portfolios?
Yes, buying activity remains notable. 148 institutions opened new positions in {ticker}, and 1712 existing holders added to their shares. The total reported buy value for the quarter amounted to $127.1B.
